{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:11:48Z","timestamp":1774563108673,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["Z141100002114050"],"award-info":[{"award-number":["Z141100002114050"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Military Health Care","award":["17BJZ08"],"award-info":[{"award-number":["17BJZ08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Prior studies have reported conflicting results on digoxin\u2019s impact on clinical outcomes and quality of life, and there are limited data from Asia. The aim of this study is to evaluate the use of digoxin and its impact on clinical outcomes and quality of life in a high-risk cohort of elderly Chinese atrial fibrillation (AF) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry is a prospective, multicentre nationwide study conducted from October 2014 to December 2018. Endpoints of interest were the composite outcome of all-cause death\/any thromboembolism (TE), all-cause death, cardiovascular death, sudden cardiac death, and TE events, as well as the quality of life. The eligible cohort for this analysis included 6391 individuals, of whom 751 (11.8%) patients were treated with digoxin. On multivariate analysis, the use of digoxin was associated with a higher odds ratio (OR) of composite outcome [OR: 1.71; 95% confidence interval (CI): 1.32\u20132.22], all-cause death (OR: 1.62; 95% CI: 1.23\u20132.14), and any TE (OR: 1.78; 95% CI: 1.08\u20132.95). Results were consistent in a subgroup of patients with diagnosed heart failure (HF) and patients with permanent AF. The use of digoxin was associated with worse health-related quality of life (mean EQ index: 0.76 \u00b1 0.19 vs. 0.84 \u00b1 0.18; P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this nationwide cohort study, digoxin use was associated with an overall higher risk of the composite outcome of all-cause death\/any TE, all-cause death, and any TE, regardless of HF diagnosis. Patients treated with digoxin had a worse health-related quality of life.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euab319","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T04:19:51Z","timestamp":1639455591000},"page":"1076-1083","source":"Crossref","is-referenced-by-count":7,"title":["Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-7751","authenticated-orcid":false,"given":"Yutao","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pulmonary Vessel and Thrombotic Disease, Sixth Medical Centre, Chinese PLA General Hospital , Beijing 100142 , China"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital , Liverpool L14 3PE , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-3187","authenticated-orcid":false,"given":"Agnieszka","family":"Kotalczyk","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital , Liverpool L14 3PE , UK"},{"name":"Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Diseases , Zabrze , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Second Medical Centre, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Vessel and Thrombotic Disease, Sixth Medical Centre, Chinese PLA General Hospital , Beijing 100142 , China"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital , Liverpool L14 3PE , UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University , Aalborg , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"2022072112090180800_euab319-B1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022072112090180800_euab319-B2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022072112090180800_euab319-B3","doi-asserted-by":"crossref","first-page":"e0193924","DOI":"10.1371\/journal.pone.0193924","article-title":"Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"13","author":"Sethi","year":"2018","journal-title":"PLoS One"},{"key":"2022072112090180800_euab319-B4","doi-asserted-by":"crossref","first-page":"h4451","DOI":"10.1136\/bmj.h4451","article-title":"Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data","volume":"351","author":"Ziff","year":"2015","journal-title":"BMJ"},{"key":"2022072112090180800_euab319-B5","doi-asserted-by":"crossref","first-page":"e2949","DOI":"10.1097\/MD.0000000000002949","article-title":"Digoxin use and adverse outcomes in patients with atrial fibrillation","volume":"95","author":"Zeng","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022072112090180800_euab319-B6","doi-asserted-by":"crossref","first-page":"e020191","DOI":"10.1136\/bmjopen-2017-020191","article-title":"Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study","volume":"8","author":"Guo","year":"2018","journal-title":"BMJ Open"},{"key":"2022072112090180800_euab319-B7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"2022072112090180800_euab319-B8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"2022072112090180800_euab319-B9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/heartjnl-2021-319496","article-title":"Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis","volume":"107","author":"Imberti","year":"2021","journal-title":"Heart"},{"key":"2022072112090180800_euab319-B10","article-title":"No real-world applicability and impact of early rhythm control for european patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry","author":"Proietti","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2022072112090180800_euab319-B11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jacep.2015.02.019","article-title":"Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation)","volume":"1","author":"Fumagalli","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2022072112090180800_euab319-B12","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF Randomized Clinical Trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA"},{"key":"2022072112090180800_euab319-B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40256-019-00350-8","article-title":"Association between digoxin use and adverse outcomes among patients in the Chinese atrial fibrillation registry","volume":"19","author":"Gao","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022072112090180800_euab319-B14","doi-asserted-by":"crossref","first-page":"e006035","DOI":"10.1161\/JAHA.117.006035","article-title":"Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 Trial","volume":"6","author":"Eisen","year":"2017","journal-title":"JAHA"},{"key":"2022072112090180800_euab319-B15","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/S0140-6736(14)61836-5","article-title":"Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"385","author":"Washam","year":"2015","journal-title":"Lancet"},{"key":"2022072112090180800_euab319-B16","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehz395","article-title":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial","volume":"40","author":"Aguirre D\u00e1vila","year":"2019","journal-title":"Eur Heart J"},{"key":"2022072112090180800_euab319-B17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2018.09.036","article-title":"Meta-analysis of effects of digoxin on survival in patients with atrial fibrillation or heart failure: an update","volume":"123","author":"Vamos","year":"2019","journal-title":"Am J Cardiol"},{"key":"2022072112090180800_euab319-B18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cjca.2014.05.009","article-title":"Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study","volume":"30","author":"Chao","year":"2014","journal-title":"Can J Cardiol"},{"key":"2022072112090180800_euab319-B19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.hrthm.2005.01.016","article-title":"Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation","volume":"2","author":"Chirinos","year":"2005","journal-title":"Heart Rhythm"},{"key":"2022072112090180800_euab319-B20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","article-title":"Increased mortality among patients taking digoxin\u2013analysis from the AFFIRM study","volume":"34","author":"Whitbeck","year":"2013","journal-title":"Eur Heart J"},{"key":"2022072112090180800_euab319-B21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jacc.2017.12.060","article-title":"Digoxin and mortality in patients with atrial fibrillation","volume":"71","author":"Lopes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022072112090180800_euab319-B22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.08.003","article-title":"Patient factors associated with quality of life in atrial fibrillation","volume":"182","author":"Randolph","year":"2016","journal-title":"Am Heart J"},{"key":"2022072112090180800_euab319-B23","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehab569","article-title":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial","volume":"42","author":"Brignole","year":"2021","journal-title":"Eur Heart J"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/7\/1076\/45041716\/euab319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/7\/1076\/45041716\/euab319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T12:11:54Z","timestamp":1658405514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/24\/7\/1076\/6506581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,7,21]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euab319","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,1,13]]}}}